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Background: Scientific evidence on treatments of chronic diseases in patients 85 years old or older is very limited,
as is available information on inappropriate prescription (IP) and its associated factors. The study aimed to describe
medicine prescription, potentially inappropriate medicines (PIM) and potentially prescribing omissions (PPO) and
their associated factors on this population.
Methods: In the context of an observational, prospective and multicentric study carried out in elderly patients
admitted to seven Spanish hospitals for a year, a sub-analysis of those aged 85 years and over was performed. To
assess PIMs, the Beers and STOPP criteria were used, and to assess PPOs, the START and the ACOVE-3 criteria were
used. To assess factors associated with IP, a multivariate logistic regression analysis was performed. Patients were
selected randomly every week on consecutive days from the hospitalization lists.
Results: A total of 336 patients were included in the sub-analysis with a median (Q1-Q3) age of 88 (86–90) years. The
median medicines taken during the month prior to admission was 10 (7–13). Forty-seven point two per cent of
patients had at least one Beers-listed PIM, 63.3% at least one STOPP-listed PIM, 53.6% at least one START-listed PPO,
and 59.4% at least one ACOVE-3-listed PPO. Use of benzodiazepines in patients who are prone to falls (18.3%) and
omission of calcium and vitamin D supplements in patients with osteoporosis (13.3%) were the most common
PIM and PPO, respectively. The main factor associated with the Beers-listed and the STOPP-listed PIM was
consumption of 10 or more medicines (OR = 5.7, 95% CI 1.8-17.9 and OR = 13.4, 95% CI 4.0-44.0, respectively). The
main factors associated with the START-listed PPO was a non-community dwelling origin (OR 2.3, 95% CI 1.0-5.0),
and multimorbidity (OR1.8, 95% CI 1.0-3.1).
Conclusions: Prescribed medicines and PIM and PPO prevalence were high among patients 85 years and over.
Benzodiazepine use in those who are prone to falls and omission of calcium and vitamin D in those with
osteoporosis were the most frequent PIM and PPO, respectively. Factors associated with PIM and PPO differed
with polypharmacy being the most important factor associated with PIM.
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Appropriate prescribing of medicines in the elderly and
especially in the very elderly is a major clinical and eco-
nomic issue. The group of the oldest old people (85 years
and over) is increasing and will increase even more in
western countries in the coming years. Therefore, health
care and appropriate use of medicines in this group is
one of the major challenges facing health care systems in
these countries [1]. In this age group there is often
significant multimorbidity [2,3], with limited scientific
evidence available on the treatment of various chronic
diseases in this aforementioned group [4]. This is due to
the lack of high quality evidence on the benefits and
safety of treatments for major chronic diseases in this
group [5,6], and their exclusion from clinical trials [7,8].
This means that most clinical practice guidelines for
major chronic diseases do not include clear recommen-
dations for the very elderly. Therefore, to treat patients
in clinical practice, an individualized approach that
incorporates a comprehensive geriatric assessment is
recommended [4,9-11].
Recently, medicines consumption in the oldest old has
been a matter of interest [12-14]. Although to our know-
ledge, no studies focusing on the use and the usefulness
in people 85 years old and over of the main criteria for
potentially inappropriate prescription medicines, have
been published.
In the context of a multicentric study focused on
inappropriate prescribing of medicines in the elderly
(patients 75 years old and over) in the month prior to
hospital admission [6], a sub-analysis of those aged
85 years old or over was performed. The goals of this
sub-analysis were: to describe the use of medicines in
this very elderly group of patients, to assess inappropri-
ate use of medicines and the associated factors, and
finally to compare the results with those obtained in the
group of 75 to 84 year old patients. The initial hypoth-
esis was that, despite a shorter life expectancy and the
lack of solid scientific evidence regarding the treatment
of most chronic conditions in the very elderly people,
polypharmacy and the percentage of potentially inappro-
priate use of medicines remain as high as those
described for the group of 75 to 84 year old.
Methods
An observational, prospective, multicentric study on a
cohort of patients hospitalised in the Internal Medicine
Services of seven Spanish hospitals was carried out for a
year (from April 2011 to March 2012). The study meth-
odology has been described in previous papers [15,16]
and this is a study focusing on the oldest old patients
(85 years or more).
In brief, patients 75 years or older admitted with an
acute illness or an exacerbation of a chronic conditionwho signed the informed consent form, were included.
Signed informed consent was obtained from patients or
caregivers in case of cognitive impairment (dementia or
delirium). Hospital admission was through either the
emergency department or directly from primary care.
Patients with a scheduled or a short-duration (less than
24 hours) admission, those seen as an outpatient by the
researcher, and those where no access was available to
primary care medical information were excluded from
the study. Each hospital included 2 patients per week
admitted with the inclusion criteria. Patients were selected
randomly every week on consecutive days from the
hospitalization lists. By design, half of the included
patients were 85 years or older. Beers criteria 2003 [17],
STOPP and START criteria [18,19] and ACOVE-3 under-
prescribing indicators for chronic conditions [16] were ap-
plied to each dataset on admission. In the study, Beers-listed
Potentially Inappropriate Medicines (PIM), when at least
one of the Beers criteria was prescribed, STOPP-listed PIM,
when at least one STOPP criteria was prescribed, START-
listed Potentially Prescribing Omissions (PPO), when at least
one START criteria was omitted, and ACOVE-3-listed PPO,
when at least one ACOVE-3 criteria was omitted. The study
was approved by the Ethics Committee of Clinical Investiga-
tion in each participating hospital (Hospital Universitari Vall
d’Hebron, Barcelona; Hospital Clínic, Barcelona; Hospital
Universitari de Bellvitge, Hospitalet de Llobregat; Hospital
Santa Creu i Sant Pau, Barcelona; Hospital Universitari
Virgen del Rocio, Sevilla; Hospital San Juan de Dios del
Aljarafe, Sevilla; Hospital General Juan Ramón Jiménez,
Huelva).
Information on a patient’s characteristics and the pre-
scribing medicines was obtained from the hospital and
the primary care electronic medical records and from in-
terviews with the patients and/or relatives, using a struc-
tured questionnaire (see online Additional file 1) [15].
Since the number of eligible patients was different for
the participating centres, analyses were weighted by fre-
quency of the eligible population in each hospital. De-
scriptive results for continuous and count variables are
shown as median, first (Q1), and third (Q3) quartiles.
Comparisons for continuous and count variables were
done using regression analyses, and for categorical ones
using Rao-Scott Chi-square tests. To examine the associ-
ation between inappropriate prescribing and potential
risk factors, a multivariate logistic regression analysis was
performed where an inappropriate prescribing indicator
was the dependent variable and sociodemographic vari-
ables, multimorbidity, number of prescription medicines
in the preceding month before hospitalization and the
other indicators of inappropriate prescription (STOPP-
listed PIM, Beers-listed PIM, ACOVE-3-listed PPO and
START-listed PPO) were the independent variables. The
adjusted Odds ratio (OR) with its 95% confidence intervals
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using the procedures for complex surveys of the SAS 9.2
program (SAS Institute Inc., Cary, NC, USA).
Results
Three hundred thirty-six out of a total of 672 patients
were included in the sub-analysis and the median (Q1-
Q3) age was 88 (86–90). The main clinical characteris-
tics of the group of the oldest old are shown in Table 1
as well as the differences between patients aged 75 to
84 years. The oldest old patients, significantly, lived more
often with their families than with their partners or alone
(p <0.001), had a worse functional status (p <0.0001) and
a poorer cognitive baseline function (p <0.001). They were
more often discharged to nursing home facilities and less
often to their homes (p <0.001).
Median (Q1-Q3) medicines taken during the month
prior to admission was 10 (7–13). The most frequently
prescribed medicine was omeprazole and the main
differences compared to the group of patients aged 75 to
84 were a higher prescription of acethylsalicylic acid
(38.1% for those 85 years and over versus 29.7% in the
group from 75 to 84 years), lorazepam (21.5% versus
15.3%), amlodipine (18.8% versus 13.2%) and paraceta-
mol (51.5% vs. 45.2%) and a lower prescription of aceno-
coumarol (16.2% versus 26.0%) and simvastatin (16.4%
versus 21.7%) (Table 2).
Forty-seven point two percent of patients aged 85 and
older had at least one Beers-listed PIM, 63.3% at least
one STOPP-listed PIM, 53.6% at least one START-listed
PPO, and 59.4% at least one ACOVE-3-listed PPO,
which was not significantly different to the group aged
75 to 84 (Table 3).
In the oldest old patients, the most frequently found
PIMs according to the Beers’ criteria was the use of
short to intermediate acting benzodiazepines in patients
with previous falls or syncope (10.7%) and the use of
long-acting benzodiazepines independent of diagnoses
or conditions (10.5%). The most commonly encountered
STOPP criteria was the use of benzodiazepines in pa-
tients who are prone to falls (18.3%) and the use of long-
term long-acting benzodiazepines (9.5%). Among the
START criteria the most frequently identified PPO were
ACE inhibitors in patients with heart failure (12.8%) and
oral anticoagulation in the presence of chronic atrial
fibrillation (12.8%). The most commonly identified PPO
using the ACOVE criteria were calcium and vitamin D
supplements in patients with osteoporosis (13.3%) and
ACE inhibitors or angiotensin-receptor blockers in pa-
tients with hypertension and comorbid vascular diseases
(10.8%).
With regard to PIM, the main difference according to
the STOPP criteria was a higher prescription of benzodi-
azepines for patients with a history of falls in the groupof the oldest old (18.4% versus 13.1% in those aged 75 to
84, p = 0.090), although the difference was not statistically
significant. Regarding PPO, the main differences were a
lower prescription of vitamin D and calcium supplements
in patients with known osteoporosis in the group of the
oldest old according to both the START (5.6% versus
11.3%, p = 0.013) and the ACOVE-3 criteria (5.7% versus
13.3%, p = 0.002), and a lower prescription of β-blocking
agents in patients with arterial hypertension and ischemic
heart disease according to the ACOVE-3 criteria (4.3%
versus 10.6%, p = 0.002) (Table 4).
The results of the multivariate regression analysis are
shown in Table 5. Only the statistically significant risk
factors are presented. In the oldest old, a prescription of
ten or more medicines was the most important inde-
pendent factor associated with an increased risk of at
least one Beers-listed PIM (OR 5.7, 95% CI 1.8-17.9). A
prescription of ten or more medicines (OR 13.4, 95% CI
4.0-44.0) and a severe dependence in basic activities of
daily living (OR 5.0, 1.1-22.1) were the independent fac-
tors associated with an increased risk of at least one
STOPP-listed PIM. Instead, multimorbidity was associated
with a reduced risk of at least one STOPP-listed PIM (OR
0.5, 0.2-0.9). In comparison to patients aged 75 to 84,
female gender was not associated with an increased risk of
PIM in the oldest old. In the oldest old, the independent
factors associated with an increased risk of at least one
START-listed PPO were a non-community dwelling (OR
2.3, 95% CI 1.0-5.0), and multimorbidity (OR 1.8, 1.0-3.1).
The only factor associated with an increased risk of at least
one ACOVE-3-listed PPO was the presence of at least one
STOPP-listed PIM (OR 2.4, 1.4-4.3). These factors were
also associated with PPO in the group of patients aged 75
to 84 with the exception of a non-community dwelling.
Discussion
This study shows that in patients 85 years and older,
polypharmacy and prevalence of inappropriate prescrib-
ing, both for PIM and PPO, were as high as those in the
younger elderly. The assessed population was very eld-
erly and with significant frailty, multimorbidity and de-
pendence in ADL as has already been described in other
studies [3,13,20].
In our study, the most frequently prescribed medicine for
patients aged 85 and over was omeprazole, but without a
significant difference in comparison with those aged 75 to
84. Among the most frequently prescribed medicines, the
consumption of paracetamol, aspirin, amlodipine and lor-
azepam was higher and that of acenocoumarol and simva-
statin lower in the very elderly in comparison to those aged
75 to 84. A lower use of anticoagulation therapy in the old-
est old population with anticoagulation criteria is one of the
most frequent causes of underprescribing in the elderly
[15,21]. However, in our study no statistically significant
Table 1 Baseline characteristics of patients (weighted percentages)
Baseline characteristics 85 and more years 75-84 years P
336 patients 336 patients
Age (median [Q1–Q3]) 88 (86–90) 80 (77–82) <0.001
Gender female (%) 60.8 53.6 0.086
Admission reason (%) 0.308
● Acute disease 54.4 50.1
● Exacerbation of chronic disease 45.6 49.9
Emergency room origin (%) 94.6 92.4 0.285
Dwelling (%) 0.004
● Community 82 91.5
● Nursing Home 18 8.5
Living with (%) <0.001
● Partner 16.3 32.4
● Family 51.4 38.2
● Single 9.6 17.6
● Others 22.7 11.8
GP visits during previous month (%) 0.012
● None 48.1 35.9
● One or two 41.7 51.8
● Three or more 10.2 12.3
Admissions during the previous month (%) 0.077
● None 85.2 84.7
● One 14.2 12.5
● Two or more 0.6 2.8
Barthel Index (median [Q1–Q3])
● Basal 60 (35–80) 80 (55–95) <0.001
● On admission 30 (5–55) 55 (20–70) <0.001
● On discharge 45 (15–65) 65 (35–80) <0.001
GDS basal (%) <0.001
● 1-2 44.1 65.1
● 3-5 41.5 25.0
● 6-7 14.4 9.9
Positive CAM on admission (%) 20.38 11.66 0.004
Failures in Pfeiffer test (median [Q1–Q3]) 3 (2–5) 2 (0–4) <0.001
Charlson Index (median [Q1–Q3]) 2 (1–4) 3 (1–4) 0.034
Multimorbidity (%) 67 59.3 0.060
Number of medicines (median [Q1–Q3]) 10 (7–13) 10 (7–14) 0.185
Number of medicines (%) 0.400
● 0-4 9.4 6.6
● 5-9 37.5 36.2
● 10 and more 53.1 57.2
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Table 1 Baseline characteristics of patients (weighted percentages) (Continued)
Discharged to (%) <0.001
● Home 66 80.4
● Nursing Home 23.7 12.4
● Another Hospital 0.7 1.2
● Died 9.6 6
GP: General Practitioner; GDS: Global Deterioration Scale; CAM: Confusion Assessment Method.
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STARTand ACOVE-3 criteria.
It is noteworthy that for patients aged 85 and over,
compared to the younger group, the main cause of PIM,
both for the Beers and the STOPP criteria, was a higher
use of benzodiazepines, especially in people with a his-
tory of falls detected using the STOPP criteria. The rela-
tionship between benzodiazepine use and an increased
risk of falls is well known [22], as is the use of benzodi-
azepines being the leading cause of PIM [9,20], although
most of these studies did not focus on the very elderly.
Recently, some authors have looked at reducing pre-
scribing benzodiazepines [23], and in some studies,
benzodiazepines’ cessation has been associated with a
reduction in falls [24]. However, these studies did not
focus on the very elderly.
Regarding PPO, the main differences in comparison to
patients aged 75 to 84, were a greater omission of calcium
and vitamin D supplements in the oldest old with osteo-
porosis according to the START and the ACOVE-3 cri-
teria, and a greater omission of β-blockers in the oldest
old with arterial hypertension and ischemic heart disease
using the ACOVE-3 criteria. A high prevalence of vitamin
D deficiency in patients aged 85 years and over [25], andTable 2 The most frequently prescribed medicines
according to age groups
85 years old and over 75 to 84 years old
Medicine % Medicine %
omeprazole 61.4 omeprazole 61.2
paracetamol 51.5 paracetamol 45.2
furosemide 47.0 furosemide 43.7
acethylsalicylic acid 38.1 acethylsalicylic acid 29.7
lorazepam 21.5 acenocoumarol 26.0
enalapril 20.8 enalapril 21.9
amlodipine* 18.8 simvastatin 21.7
metformin 18.6 metformin 21.7
nitroglycerin nitrate 17.4 ipratropium bromide 19.1
simvastatin 16.4 hydrochlorothiazide 16.9
ipratropium bromide 16.3 metamizole 16.8
acenocoumarol 16.2 lorazepam 15.3
hydrochlorothiazide 15.8 nitroglycerin nitrate 14.8
*Amlodipine 13.26% in those aged 75 to 84.the association between hypovitaminosis D and various
health problems in the elderly have been described [26].
Moreover, omission of calcium and vitamin D supple-
ments in the elderly with osteoporosis has been the
leading cause of PPO in different studies [21,27]. This is
relevant, taking into account the benefit of calcium and
vitamin D supplements in preventing bone loss and frac-
tures in elderly people with osteoporosis [28,29], although
once again, these studies were not performed on the very
elderly. The higher omission of β-blockers in the oldest
old with hypertension and ischemic heart disease may be
due to more frequent use of other antihypertensives in
this frail group.
The main factor associated with PIM in both age
groups was polypharmacy, especially when 10 or more
medicines were taken. The strong association between
polypharmacy and PIMs [21,30] and also the higher
prevalence of PIM when STOPP criteria was used in
comparison to the Beers criteria have already been
reported on in other studies [9,21]. The association
between a severe dependency in ADL and PIM found in
our study can be explained, at least in part, by the high
prevalence of dementia in this population.
Regarding PPO in patients aged 85 years or older, the
relevant findings in our study were the higher ACOVE-3
PPO criteria prevalence, and the association between a
nursing home origin and multimorbidity with the
START criteria. That is, patients from a nursing home
and those with multimorbidity had a higher risk of
underprescription. The lack of association between poly-
pharmacy and PPO is well known [30], as is the scarce
scientific evidence available regarding risk factors associ-
ated with underprescribing. The association with multi-
morbidity has also been described in other studies [21],
and other described factors have been advanced age
[19,21], and female gender [19]. The high proportion ofTable 3 Prevalence of PIM and PPO according to the
criteria
Criteria 85 years and over % 75 to 84 years old % P
Beers 47.28 53.76 P = 0.126
STOPP 63.36 60.47 P = 0.482
START 53.68 49.65 P = 0.342
ACOVE3 59.40 54.91 P = 0.289
Table 4 Main potentially inappropriate medicines (PIM) and potentially prescribing omissions (PPO) in patients aged
85 years and over compared with those aged 75 to 84 years
Disease or condition Drug 85 years
and over %
75 – 84
years %
p
Beers list PIM
Syncope or falls Short- to intermediate-acting benzodiazepine and tricyclic antidepressants 10.7 9.8 0.712
Independent diagnosis Long-acting benzodiazepines 10.5 12.7 0.268
STOPP list PIM
Drugs that adversely affect
those prone to falls
Benzodiazepines 18.4 13.2 0.090
Central nervous system
and psychotropic drugs
Long-term (i.e. >1 month), long-acting benzodiazepines 9.5 11.7 0.687
Cardiovascular system Aspirin at dose >150 mg day 8.6 4.9 0.106
Cardiovascular system Aspirin with no history of coronary, cerebral or peripheral arterial symptoms or
occlusive arterial event
7.8 7.5 0.909
START list PPO
Cardiovascular system ACE inhibitor with chronic heart failure 12.8 13.5 0.750
Cardiovascular system Warfarin in the presence of chronic atrial fibrillation 12.8 10.3 0.343
Musculoskeletal system Calcium and vitamin D supplement in patients with known osteoporosis 11.3 5.6 0.013
Endocrine system Antiplatelet therapy in diabetes mellitus if one or more coexisting major
cardiovascular risk factor present
8.8 10.3 0.530
ACOVE 3 list PPO
Osteoporosis IF a VE has osteoporosis, THEN he or she should be prescribed calcium and
vitamin D supplements
13.3 5.7 0.002
Hypertension IF a VE with HTN has a history of HF, left ventricular hypertrophy, IHD, chronic
kidney disease, or cardiovascular accident, THEN he or she should be treated with
an ACE inhibitor or ARB
12.6 9.9 0.289
Stroke and atrial fibrillation IF a VE has chronic atrial fibrillation and is at medium to high risk for stroke, THEN
anticoagulation should be offered.
10.7 8.1 0.242
Hypertension IF a VE with HTN has IHD, THEN treatment with a beta-blocker should be
recommended or documentation of why it should not be provided.
10.6 4.3 0.002
Osteoporosis IF a female VE has osteoporosis, THEN she should be treated with
bisphosphonates, raloxifene, calcitonin, hormone replacement therapy, or
teriparatide
10.5 7.4 0.163
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homes is known about [31]. Moreover, the implementa-
tion of the STOPP/START criteria has been associated
with a reduction in the number of drugs and falls in this
population [32]. The association between underprescrib-
ing and a nursing home origin found in our study is
curious. In contrast, a low START-listed PPO prevalence
in patients with dementia has been described [21]. The
authors of this study argued that patients with dementia
are probably more often institutionalized in nursing
home facilities with more organized pharmaceutical care.
More studies are needed to clarify the association
between underprescribing and a nursing home origin.
Something new that we have found is a link between
PIM and PPO in a very elderly population with polyphar-
macy. This may be explained because a large percentage
of patients in our study had PIM and PPO at the same
time [15]. However, this is a surprising finding becauserisk factors associated with PIM and PPO did not match
in several other studies [15,18,19,21]. More information
on risk factors simultaneously associated with PIM and
PPO in very elderly patients with polypharmacy is needed.
Moreover, the association between multimorbidity and
PPO has been previously reported on in the elderly, but
the inverse association with PIM is more striking. It seems
that in the very elderly with multimorbidity, physicians
avoid medicines included in the PIM criteria with a low
level of scientific evidence on their efficacy and/or with
better alternatives.
In the elderly patients with multimorbidity, and espe-
cially in the oldest old, the usefulness of underprescrib-
ing tools is controversial. A high prevalence of medicine
omission is often described when they are systematically
used in these patients [19,21], although, as discussed
above, the available evidence on treatments of chronic
diseases in these patients are low or insufficient [4].
Table 5 Results of the multivariate regression analysis
85 years old and over 75 to 84 years old
Associated factor OR (95% CI) p Associated factor OR (95% CI) p
Beers Beers
Number of medicines Number of medicines
● 10 or more 5.7 (1.8-17.9) 0.003 ● 5 - 9 6.3 (1.1-34.4) 0.035
● 10 or more 11.0 (2.0- 59.7) 0.006
Female gender 1.9 (1.1-3.1) 0.014
START-listed PPO 1.8 (1.0-2.9) 0.027
STOPP STOPP
Number of medicies Number of medicines
● 5 - 9 5.7 (1.8-17.8) 0.003 ● 10 or more 5.1 (1.5-16.8) 0.007
● 10 or more 13.4 (4.0-44.0) <0.001 ACOVE-3-listed PPO 2.2 (1.2-3.6) 0.004
Severe dependence in
ADL 5.0 (1.1-22.1) 0.031
Multimorbidity 0.5 (0.2-0.9) 0.045
START START
Non-community dwelling 2.3 (1.0-5.0) 0.030 Multimorbidity 1.9 (1.0-3.2) 0.027
Multimorbidity 1.8 (1.0-3.1) 0.040
ACOVE-3 ACOVE-3
STOPP-listed PIM 2.5 (1.4-4.3) 0.001 STOPP-listed PIM 2.2 (1.2-3.8) 0.004
Only the statistically significant risk factors associated to PIM and PPO tools are presented.
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out on a large group of very elderly people and is a topic
that has infrequently been investigated. Secondly, a
rigorous methodology in both the geriatric and the
pharmacological assessment of patients was applied, and
thirdly it was a multicentric study involving seven
hospitals lasting a year.
This study also has some limitations. Firstly, the Beers’
criteria version 2003 was used, and currently there is a
new one [33] which only appeared once the study was
initiated. A new version of the STOPP/START criteria has
also been published very recently, although the indicators
identified in our study as the most prevalent in the oldest
old remain unchanged in the new version [34]. Secondly,
only patients admitted to medical units in hospitals were
included and they are not representative of the very
elderly community dwelling patients. Finally, the conse-
quences of inappropriate prescribing were not analysed.
Conclusions
In our study, a high prevalence of polypharmacy, PIM and
PPO in patients aged 85 years and over has been de-
scribed. In addition, regarding PIM, a higher prevalence
when STOPP criteria were use in comparison to the Beers
criteria, use of benzodiazepines as the primary cause for
PIM, especially in people prone to falls, and a strong asso-
ciation with polypharmacy were found. Regarding PPO,omission of calcium plus vitamin D supplements in
patients with osteoporosis as the primary cause for PPO,
and a paucity of factors associated with PPO were re-
ported on in this population. This multicentric study was
carried out on a large cohort of the very elderly, an infre-
quently investigated group, and a comprehensive geriatric
and pharmacological assessment of patients was applied.
To improve the available information on the risk factors
associated with PIM and especially with PPO, to analyze
its consequences, to refine and adjust the PIM and PPO
criteria, and finally, to carry out interventions to improve
prescribing in this very elderly population, more research
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